Kallikrein-related peptidases (KLKs) in gastrointestinal cancer: Mechanistic and clinical aspects

Kallikrein-related peptidases (KLKs) in gastrointestinal cancer: Mechanistic and clinical aspects
复制标题

DOI:
10.1160/th12-11-0791
复制
发表时间:
2013-09-01
影响因子:
6.7
通讯作者:
Scorilas, Andreas
Scorilas, Andreas
中科院分区:
医学2区
文献类型:
--
作者:
Kontos, Christos K.;Mavridis, Konstantinos;Scorilas, Andreas

文献摘要

被引文献

相似文献

人组织钾化因子(KLK1)和钾化因子相关肽酶(KLKs)是分泌丝氨酸蛋白酶,在包括消化系统在内的不同系统中具有不同的表达模式和生理作用。胃肠道恶性肿瘤中klk的异常表达及其在癌变过程中的意义,包括细胞生长调节、血管生成、侵袭和转移,促使科学家们研究其作为癌症生物标志物的潜力。不同KLKs的表达与胃癌、结直肠癌、胰腺癌、肝癌和食管癌患者的各种临床病理参数相关。此外,一些klk在这些人类恶性肿瘤中具有显著的有利或不利的预后价值。确定新的诊断、预后和预测生物标志物将对临床决策做出最大贡献,因为胃肠道癌症的早期诊断和手术后复发的早期发现对于患者的有效治疗和积极的临床结果至关重要。本文简要介绍了klk在胃癌、结直肠癌、胰腺癌、肝癌和食管癌中的功能作用,并描述了klk在这些人类恶性肿瘤中作为潜在肿瘤生物标志物的现状。
The human tissue kallikrein (KLK1) and kallikrein-related peptidases (KLKs) are secreted serine proteases with diverse expression patterns and physiological roles in different systems, including the digestive system. The aberrant expression of KLKs in gastrointestinal malignancies as well as their implication in carcinogenesis including cell growth regulation, angiogenesis, invasion, and metastasis, has prompted scientists to investigate their potential as cancer biomarkers. Expression of distinct KLKs is associated with various clinic-pathological parameters of patients with gastric, colorectal, pancreatic, hepatic, and esophageal cancer. Moreover, several KLKs possess significant favourable or unfavourable prognostic value in these human malignancies. Identification of novel diagnostic, prognostic and predictive biomarkers will contribute utmost to clinical decision-making, since early diagnosis of gastrointestinal cancer and early detection of recurrence following surgery are critical for the effective treatment of patients and for a positive clinical outcome. The current review provides a brief overview of the functional role of KLKs in gastric, colorectal, pancreatic, hepatic, and esophageal cancer, and describes the current status of KLKs as potential tumour biomarkers in these human malignancies.